Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PBM Psyence Biomedical Ltd

Post-Mkt 04-08 19:33:05 EDT

2.49

-0.01

-0.40%

盘后2.49

+0.00-0.05%

18:51 EDT

High2.65	Low2.40	Vol21.13K
Open2.65	D1 Closing2.50	Amplitude9.92%
Mkt Cap2.86M	Tradable Cap2.42M	Total Shares1.15M
T/O53.74K	T/O Rate2.18%	Tradable Shares970.70K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PBM","market":"US","secType":"STK","nameCN":"Psyence Biomedical Ltd","latestPrice":2.49,"timestamp":1775678400000,"preClose":2.5,"halted":0,"volume":21129,"hourTrading":{"tag":"盘后","latestPrice":2.4887,"preClose":2.49,"latestTime":"18:51 EDT","volume":193,"amount":473.87820750000003,"timestamp":1775688719330,"change":-0.0013,"changeRate":-0.000522,"amplitude":0.035422},"delay":0,"changeRate":-0.003999999999999915,"floatShares":970699,"shares":1147100,"eps":-34.781662,"marketStatus":"Post-Mkt","change":-0.01,"latestTime":"04-08 19:33:05 EDT","open":2.65,"high":2.65,"low":2.402,"amount":53739.4183098,"amplitude":0.0992,"askPrice":2.75,"askSize":200,"bidPrice":2.27,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-34.781662,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1775692800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":2.5,"preHourTrading":{"tag":"盘前","latestPrice":2.71,"preClose":2.5,"latestTime":"09:20 EDT","volume":2088,"amount":5439.603312,"timestamp":1775654414876,"change":0.21,"changeRate":0.084,"amplitude":0.076},"postHourTrading":{"tag":"盘后","latestPrice":2.4887,"preClose":2.49,"latestTime":"18:51 EDT","volume":193,"amount":473.87820750000003,"timestamp":1775688719330,"change":-0.0013,"changeRate":-0.000522,"amplitude":0.035422},"volumeRatio":1.406443},"requestUrl":"/m/hq/s/PBM/wiki","defaultTab":"wiki","newsList":[{"id":"2625944115","title":"Psyence Biomedical Ltd - Expands Australian Clinical Site Network to Five Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2625944115","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625944115?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:16","pubTimestamp":1775654210,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625944112","title":"Psyence BioMed expands Australia clinical trial network to five sites for NPX-5 program","url":"https://stock-news.laohu8.com/highlight/detail?id=2625944112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625944112?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:15","pubTimestamp":1775654154,"startTime":"0","endTime":"0","summary":"Psyence BioMed expanded Australian clinical site network to five sites from three to support NPX-5 clinical activities.Ramsay Health Care, NeuroCentrix added to strengthen recruitment, accelerate enrollment for Phase IIb trial.Phase IIb study evaluates natural psilocybin for Adjustment Disorder in cancer patients receiving palliative care.Trial currently runs at sites in Perth, Melbourne, with initial patient dosing starting in late 2025.Program supply uses GMP-compliant NPX-5 psilocybin capsules manufactured at PsyLabs GMP-controlled facility.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLbwkCbW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","SG9999014039.USD","NDAQ","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK7113","PBM","LU0314104364.USD","RHC.AU","BK4139","LU2210150020.SGD","BK4585","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014005.SGD","BK4112","BK4588","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624528365","title":"A Look At Cigna Group’s Valuation After PBM Reform Progress And New CEO Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624528365","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624528365?lang=en_us&edition=fundamental","pubTime":"2026-04-02 07:28","pubTimestamp":1775086120,"startTime":"0","endTime":"0","summary":"Recent analyst commentary around pharmacy benefit manager reform, a rebate-free model and a leadership change has put Cigna Group (CI) back in focus for investors watching how regulatory shifts shape earnings visibility.\nSee our latest analysis for Cigna Group.\nThose regulatory updates and the CEO transition are playing out against a softer trading backdrop, with a 30 day share price return of an 8.09% decline and a 1 year total shareholder return of a 17.76% loss suggesting momentum has...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/172899-main-header/1756254126085","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/172899-main-header/1756254126085"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/a-look-at-cigna-groups-valuation-after-pbm-reform-progress-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/a-look-at-cigna-groups-valuation-after-pbm-reform-progress-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0058720904.USD","IE00B19Z3581.USD","LU0289739699.SGD","CI","IE00B19Z3B42.SGD","LU2065732104.USD","BK4097","BK4196","LU0868494617.USD","LU1059921491.USD","PRGS","BK4588","PBM","LU1261432733.SGD","IE00BSNM7G36.USD","BK4585","IE0002270589.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622869076","title":"Mochi Finance founder offloads 550K CVX as fraud claims deepen across DeFi","url":"https://stock-news.laohu8.com/highlight/detail?id=2622869076","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622869076?lang=en_us&edition=fundamental","pubTime":"2026-03-26 22:46","pubTimestamp":1774536390,"startTime":"0","endTime":"0","summary":"Mochi founder Azeem Ahmed sold 550K CVX from a Curve-linked stash as on-chain probes allege over $8M in diverted rewards and $54M in DeFi losses.Mochi Finance founder Azeem Ahmed sold about 550,285 CVX for roughly $946,000, pushing the token down more than 10%.The CVX stack traces back to a 2021 Curve pool drain that left liquidity providers with an estimated $54 million in losses.Beyond staking flows, investigators allege that about 2,198 ETH—worth roughly $6.67 million at the time—and $471,429 in USDC were drained from Mochi/ETH liquidity pools and never returned to depositors, while airdrops fr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/mochi-finance-founder-offloads-550k-cvx-as-fraud-claims-deepen-across-defi/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/mochi-finance-founder-offloads-550k-cvx-as-fraud-claims-deepen-across-defi/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["LU0630314457.HKD","IE00BGHQF524.EUR","LU2129689605.HKD","LU0070302665.USD","LU1280957306.USD","LU0300736492.USD","LU1430597077.USD","SAFE","LU2129689514.USD","BK4550","LU0208291251.USD","BK4534","IE00B7SZLL34.SGD","LU1066053197.SGD","LU2381873111.SGD","IE000M9KFDE8.USD","LU2133065610.SGD","LU0266512127.USD","LU0612318971.USD","LU0612318385.USD","IE0002270589.USD","BK4234","SG9999002521.SGD","IE00B2Q91V27.USD","LU1496350502.SGD","LU0256863811.USD","BK4139","LU1116320737.USD","LU0234572021.USD","CVX","BK4588","BK4084","BK4581","PBM","LU0942090050.USD","LU1074936037.SGD","LU1496350171.SGD","LU2129689431.USD","LU1116320901.HKD","LU0320765646.SGD","LU0320765489.SGD","BK4570","LU0640476718.USD","BK4566","IE00B19Z3B42.SGD","IE00B3CCJ963.GBP","LU0368265418.SGD","BK4559","LU1929549753.HKD","LU0788109394.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622835066","title":"Psyence Group; GoldCoast private placement raises $2.78 million on $0.85 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2622835066","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622835066?lang=en_us&edition=fundamental","pubTime":"2026-03-26 14:24","pubTimestamp":1774506295,"startTime":"0","endTime":"0","summary":"Psyence reported that GoldCoast completed a non-brokered private placement of 3,280,140 common shares at CAD 0.85 per share.The second tranche raised gross proceeds of CAD 2.78 million.Including a previously completed brokered tranche of CAD 5.83 million, aggregate gross proceeds totaled CAD 8.6 million.The financing was completed in connection with GoldCoast’s proposed amalgamation with Psyence.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Group Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3HNsl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622001336","title":"Should FTC Insulin Settlement And PBM Lawsuit Shift How Investors View CVS Health’s (CVS) Risk-Reward Profile?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001336","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622001336?lang=en_us&edition=fundamental","pubTime":"2026-03-26 02:14","pubTimestamp":1774462482,"startTime":"0","endTime":"0","summary":"CVS Health recently reached a proposed settlement with the Federal Trade Commission over insulin pricing practices in its Caremark pharmacy benefit manager unit, while also facing a new class action lawsuit alleging improper formulary-related fees. \nAt the same time, CVS Health’s board affirmed its quarterly US$0.665 dividend and added former Elevance Health CFO John E. Gallina as an audit committee financial expert, underscoring governance and capital-return priorities amid regulatory...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/93625-main-header/1756253484610","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/93625-main-header/1756253484610"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/should-ftc-insulin-settlement-and-pbm-lawsuit-shift-how-inve","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/should-ftc-insulin-settlement-and-pbm-lawsuit-shift-how-inve","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","LU0432979614.USD","LU1571399168.USD","BK4023","LU0070302665.USD","AGIX","IE00B7SZLL34.SGD","BK4585","AIPO","BK4139","BK4196","BK4528","IE0002270589.USD","LU1699723380.USD","CHAT","LU0061475181.USD","CVS","LU0320765489.SGD","LU1983299246.USD","BK4588","BK4551","BK4543","LU1059921491.USD","LU0006061336.USD","BK4587","CVS.AU","IE00BSNM7G36.USD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU0211331839.USD","LU0162691827.USD","AIYY","LU0072461881.USD","BK4211","BK4581","LU0208291251.USD","PBM","BK4550","IE00B19Z3581.USD","AI","IE00BZ1G4Q59.USD","FTC","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620280915","title":"Psyence Group says GoldCoast raises CAD 5.83 million in financing tied to proposed amalgamation","url":"https://stock-news.laohu8.com/highlight/detail?id=2620280915","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620280915?lang=en_us&edition=fundamental","pubTime":"2026-03-18 15:20","pubTimestamp":1773818407,"startTime":"0","endTime":"0","summary":"Psyence has a definitive amalgamation agreement with GoldCoast, dated Nov. 21, 2025 and amended Feb. 24, 2026. GoldCoast completed a brokered private placement of 6,853,840 shares at CAD 0.85 per share for gross proceeds of CAD 5.83 million. GoldCoast expects to complete a non-brokered private placement at the same price in tranches over the next several weeks. The financing satisfied a condition precedent to the proposed amalgamation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Group Inc. published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL62lgvy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618294000","title":"Psyence BioMed Plans to Advance Vertically Integrated Platform and Product and Clinical Development Program, Targeting Phase IIb Trial Execution and Regulatory Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2618294000","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618294000?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:25","pubTimestamp":1773235523,"startTime":"0","endTime":"0","summary":"Psyence BioMed Plans to Advance Vertically Integrated Platform and Product and Clinical Development Program, Targeting Phase IIb Trial Execution and Regulatory Readiness. Psyence Biomedical Ltd. said it plans to continue executing its vertically integrated pharmaceutical platform and advance its product and clinical development program, including implementing a Phase IIb clinical trial on schedule while maintaining required regulatory and other consents. The company also indicated it aims to support long-term competitiveness and reduce strategy execution risk through operational and commercial readiness of its integrated model, and noted that a share consolidation may be implemented in the future, though timing is uncertain.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL25g3Vy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618169940","title":"Psyence Biomedical appoints Sashank Pillay to board after Seth Feuerstein resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2618169940","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618169940?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:15","pubTimestamp":1773234919,"startTime":"0","endTime":"0","summary":"Psyence BioMed said Seth Feuerstein resigned as a director effective Feb. 20, 2026. The company appointed Sashank Pillay to fill the board vacancy. Pillay previously served as a country manager and community and government relations liaison for governmentally licensed psilocybin cultivation and production facilities in Southern Africa.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL6LtrVn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","BK4139","BK4588","IE00B3QW5Z07.USD","PBM","SG9999014005.SGD","SG9999014013.SGD","BK4585","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","BK4112","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618151940","title":"Corporate Update: Psyence Biomed Advances Vertically Integrated Pharmaceutical Platform Following Psylabs Export Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2618151940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618151940?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:15","pubTimestamp":1773234900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA7WZM0S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616268483","title":"BRIEF-Psyence Biomed Announces Export Of Gmp-Manufactured Natural Psilocybin (Npx-5) To Australia For Ongoing Phase Iib Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616268483","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616268483?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:15","pubTimestamp":1772547342,"startTime":"0","endTime":"0","summary":"BRIEF-Psyence Biomed Announces Export Of Gmp-Manufactured Natural Psilocybin (Npx-5) To Australia For Ongoing Phase Iib Clinical TrialMarch 3 (Reuters) - Psyence Biomedical Ltd PBM.O:PSYENCE BIOMED AN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUAPKD6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616832502","title":"Psyence Biomed Announces Export of Gmp-Manufactured Natural Psilocybin (Npx-5) to Australia for Ongoing Phase Iib Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616832502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616832502?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:15","pubTimestamp":1772547300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUAPKD6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616933331","title":"Psyence Biomedical Names Sashank Pillay to Board After Seth Feuerstein Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2616933331","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616933331?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:08","pubTimestamp":1772453298,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. said director Seth Feuerstein resigned from its board effective Feb. 20, 2026. The company appointed Sashank Pillay to fill the vacancy, and he will serve on the audit, compensation, and nominating and corporate governance committees.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL7bdQS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613194127","title":"Psyence extends GoldCoast amalgamation deadline to May 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613194127","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613194127?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:42","pubTimestamp":1771936974,"startTime":"0","endTime":"0","summary":"Psyence Group Inc. has signed an amending agreement with GoldCoast Resource Corp. and its subsidiary Psyence Therapeutics Corp. to extend the timeline for their proposed three-cornered amalgamation. The deadline to hold required shareholder meetings was pushed to April 30, 2026, and the outside date to complete the deal was extended to May 31, 2026. The amendment also lowers Psyence’s minimum cash condition at closing to C$250,000 from C$400,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Group Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDLbSLjwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613183632","title":"Psyence BioMed to Invest $5 Million in PsyLabs via Share-for-Share Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2613183632","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613183632?lang=en_us&edition=fundamental","pubTime":"2026-02-21 06:20","pubTimestamp":1771626013,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. said Psyence Labs Ltd. exercised a previously disclosed put option requiring Psyence BioMed to make a $5.0 million equity investment in PsyLabs at fair market value via a non-cash share-for-share exchange. Under the terms, Psyence BioMed will receive 2,900 PsyLabs shares valued at $1,724 per share, and will issue 1,146,159 Psyence BioMed common shares to PsyLabs, priced using a 30-day VWAP of $4.36 per share. Following issuance, PsyLabs is expected to own about 49.98% of Psyence BioMed’s outstanding shares, with closing targeted on or about Feb. 25, 2026, subject to customary conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this ne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL3nq0VX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4112","BK4139","IE00BGHQF748.EUR","IE00BKPKM429.USD","PBM","SG9999014021.USD","SG9999014005.SGD","NDAQ","BK4585","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","LU0314104364.USD","BK4588","LU2095319765.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613218888","title":"Psyence Biomed Announces Exercise of Put Option by Psylabs and Strategic Equity Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2613218888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613218888?lang=en_us&edition=fundamental","pubTime":"2026-02-21 06:20","pubTimestamp":1771626000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nTUABVCTCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613218361","title":"Press Release: Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2613218361","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613218361?lang=en_us&edition=fundamental","pubTime":"2026-02-21 06:20","pubTimestamp":1771626000,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 20, 2026  -- Psyence Biomedical Ltd.  , a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds  has exercised its rights under a previously disclosed put option agreement , pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement.The Put Option Agreement was previously disclosed by Psyence BioMed and forms part of the broader strategic and commercial relationship between the two vertically integrated companies, including licensing and supply arrangements relating to pharmaceutical-grade psychedelic compounds.No cash consideration will be exchanged in connection with the Share-for-Share Exchange. Following the issuance of the PBM Shares, PsyLabs will beneficially own approximately 4","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["API","EQR","BK4588","BK4585","BK4023","BK4551","PBM","BK4535","BK4215","BK4139","BK4503"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612486402","title":"Psyence BioMed Shareholders Approve Up to 250-for-1 Share Consolidation Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=2612486402","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612486402?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:20","pubTimestamp":1771503620,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. said shareholders approved a special resolution authorizing its board to implement one or more consolidations of the company’s common shares at a ratio of up to 250-to-1. The company said it will provide additional disclosure if and when the board decides to proceed, including the final ratio and effective date, subject to applicable approvals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDLkwTrf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612468109","title":"Psyence Biomedical announces results of annual, special meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2612468109","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612468109?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:27","pubTimestamp":1771338462,"startTime":"0","endTime":"0","summary":"Psyence Biomedical (PBM) announced the voting results from its Annual and Special Meeting of Shareholders, held at 9:00 a.m. Eastern Time on Februa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psyence-biomedical-announces-results-of-annual-special-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psyence-biomedical-announces-results-of-annual-special-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612450758","title":"Press Release: Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2612450758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612450758?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:15","pubTimestamp":1771337700,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 17, 2026  -- Psyence Biomedical Ltd.  , a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders , held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors .The Company will provide additional disclosure if and when the Board determines to implement any share consolidation, including the final consolidation ratio and effective date, subject to applicable regulatory and exchange approvals.Further details regarding the matters voted on at the Meeting are set out in the Company's management information circular, which is available under the Company's profile on EDGAR.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacificbooker.bc.ca","stockEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":-0.004},{"period":"3month","weight":-0.4937},{"period":"6month","weight":-0.8919},{"period":"1year","weight":-0.8854},{"period":"ytd","weight":-0.4691}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":-0.0196},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0178},{"period":"1year","weight":0.307},{"period":"ytd","weight":-0.0333}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.237918},{"month":2,"riseRate":0.4,"avgChangeRate":-0.252579},{"month":3,"riseRate":0.6,"avgChangeRate":0.107838},{"month":4,"riseRate":0.6,"avgChangeRate":-0.084819},{"month":5,"riseRate":0.5,"avgChangeRate":0.047065},{"month":6,"riseRate":0.75,"avgChangeRate":-0.123687},{"month":7,"riseRate":0.75,"avgChangeRate":0.230875},{"month":8,"riseRate":0.5,"avgChangeRate":-0.181154},{"month":9,"riseRate":0.75,"avgChangeRate":-0.153581},{"month":10,"riseRate":0.25,"avgChangeRate":-0.079288},{"month":11,"riseRate":0.25,"avgChangeRate":-0.211015},{"month":12,"riseRate":0.25,"avgChangeRate":-0.267978}],"exchange":"NASDAQ","name":"Psyence Biomedical Ltd","nameEN":"Psyence Biomedical Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Psyence Biomedical Ltd,PBM,Psyence Biomedical Ltd股票,Psyence Biomedical Ltd股票老虎,Psyence Biomedical Ltd股票老虎国际,Psyence Biomedical Ltd行情,Psyence Biomedical Ltd股票行情,Psyence Biomedical Ltd股价,Psyence Biomedical Ltd股市,Psyence Biomedical Ltd股票价格,Psyence Biomedical Ltd股票交易,Psyence Biomedical Ltd股票购买,Psyence Biomedical Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}